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Clinical efficacy of anti-cytokine therapy in rheumatoid arthritis
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SUMMARY
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by the pro-
gressive destruction of joints. Cytokines such as tumor necrosis factor (TNF)-α, interleukin
(IL)-1, IL-6 and IL-8 have a critical role in the pathogenesis of RA. Recently, etanercept and
infliximab, which block the action of TNF-α, can reduce the disease activity of RA. They
act more rapidly to decrease symptoms and slow joint damage in patients with early active
RA than methotrexate. This article describes recent studies on anti-cytokine therapy in
RA.
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